Progressive myoclonic epilepsy type 3

Progressive myoclonic epilepsy type 3 (PME3), also known as progressive myoclonic epilepsy with nerve deafness, is a rare inherited neurological disorder caused by mutations in the KCTD7 gene (also referred to as EPM3). This condition belongs to the group of progressive myoclonic epilepsies, which are characterized by the combination of myoclonus (sudden, brief involuntary muscle jerks), epileptic seizures, and progressive neurological decline. PME3 primarily affects the central nervous system and may also involve the auditory system. The disease typically presents in childhood with myoclonic seizures that are often difficult to control with standard antiepileptic medications. Over time, affected individuals may develop progressive cognitive decline, ataxia (impaired coordination and balance), and in some cases sensorineural hearing loss. The myoclonus tends to worsen over time and can significantly impair daily functioning and quality of life. Electroencephalography (EEG) typically shows epileptiform abnormalities consistent with progressive myoclonic epilepsy. There is currently no cure for PME3, and treatment is primarily symptomatic and supportive. Management focuses on seizure control using antiepileptic drugs, though seizures in progressive myoclonic epilepsies are often refractory to treatment. Valproate and other broad-spectrum antiepileptic medications may be used, while certain sodium channel blockers may worsen myoclonus and should be avoided. Physical therapy, occupational therapy, and educational support are important components of comprehensive care. Genetic counseling is recommended for affected families.

Common questions about Progressive myoclonic epilepsy type 3